Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?
Georg Lenz* and Martin Dreyling
Correspondence *University Hospital, Grosshadern Department of Internal Medicine III, Ludwig-Maximilians-University, Marchioninistrasse 15, 81377 Munich, Germany
Email georg.lenz@med.uni-muenchen.de
This article has no abstract so we have provided the first paragraph of the full text.
MCL accounts for approximately 5–10% of all non-Hodgkin's lymphoma cases and is characterized by an aggressive clinical course and poor prognosis with virtually no long-term survivors. Conventional chemotherapy has failed to substantially alter the natural course of the disease and represents a non-curative approach.1 Thus, new strategies in the treatment of MCL are urgently warranted to further improve the long-term perspectives of MCL.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.